proPSMA
PSMA PET beat conventional imaging for prostate cancer staging, the trial that changed the staging paradigm
Quick Answer
proPSMA (Hofman et al., Lancet 2020) was the prospective randomized trial that showed ⁶⁸Ga-PSMA-11 PET/CT is more accurate than conventional imaging (CT plus bone scan) for the initial staging of high-risk prostate cancer, with less radiation and fewer equivocal findings. It provided the high-level evidence that moved PSMA PET into first-line staging and changed management in a substantial minority of patients — the diagnostic counterpart to the therapeutic PSMA trials.
The trial
Design: prospective, randomized, multicentre study of 302 men with high-risk prostate cancer before curative-intent surgery or radiotherapy. Patients underwent ⁶⁸Ga-PSMA-11 PET/CT or conventional imaging (CT + bone scan) first, then crossed over. Primary endpoint: accuracy for nodal/distant metastases (against a composite reference standard).
Key result
PSMA PET/CT had much higher accuracy (~92% vs ~65%) than conventional imaging, with fewer equivocal results, lower radiation exposure, and greater management impact — conventional imaging changed management in a smaller fraction, while PSMA PET altered planned treatment in roughly a quarter of men. PSMA PET was superior for both nodal and distant disease.
Why it mattered
proPSMA delivered level-1 evidence that PSMA PET outperforms the historical CT + bone-scan standard for staging high-risk prostate cancer, catalyzing its adoption into guidelines and routine practice. Together with the therapy trials (VISION, TheraP), it made PSMA the defining target of modern prostate-cancer nuclear medicine — accurate staging with the same target later used for therapy.
Context & caveats
proPSMA studied initial staging of high-risk disease; PSMA PET's role in biochemical recurrence (especially at low PSA) is supported by separate detection-rate literature. Benign PSMA uptake (ganglia, ribs, healing bone) remains an interpretive caveat.
Self-Check
Q1. What did proPSMA compare and conclude?
Answer: ⁶⁸Ga-PSMA-11 PET/CT vs conventional imaging (CT + bone scan) for staging high-risk prostate cancer — PSMA PET was more accurate (~92% vs ~65%) with less radiation and fewer equivocal findings.
Q2. Why is proPSMA a landmark for imaging (not just therapy)?
Answer: It gave level-1 randomized evidence that PSMA PET beats the conventional staging standard, moving it into first-line staging and guidelines.
Q3. Beyond accuracy, what practical advantages did PSMA PET show?
Answer: Lower radiation, fewer equivocal results, and greater management impact (changing planned treatment in a meaningful fraction of patients).
Q4. How does proPSMA connect to the PSMA therapy trials?
Answer: The same PSMA target used for accurate staging is the target treated by ¹⁷⁷Lu-PSMA therapy — imaging and therapy as a matched theranostic pair.
Key References
- Hofman MS, et al. Prostate-specific membrane antigen PET-CT in high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA). Lancet 2020;395:1208–1216. doi:10.1016/S0140-6736(20)30314-7
Evidence & sources
https://nuc.med/propsma-trial/ Report an issue